Benefit of early initiation of disease-modifying therapy in community-based patients with suspected heart failure
In community-based patients with suspected HF and elevated NT-proBNP, the early initiation of an SGLT2i and an MRA in patients with a pre-existing non-HF-related indication for treatment may reduce the risk of early adverse outcomes whilst awaiting diagnostic echocardiography. These findings suggest a simple clinical strategy with potentially large public health benefits.
Authors
- Kieran F. Docherty (ORCID: https://orcid.org/0000-0002-5446-9969)
- Antoni Bayes-genis A (ORCID: https://orcid.org/0000-0002-3044-197X)
- Pardeep S. Jhund (ORCID: https://orcid.org/0000-0003-4306-5317)
- John J.V. McMurray (ORCID: https://orcid.org/0000-0002-6317-3975)
- Morten Schou (ORCID: https://orcid.org/0000-0002-4271-2466)
- Lars Køber (ORCID: https://orcid.org/0000-0002-6635-1466)
- Alasdair Henderson (ORCID: https://orcid.org/0000-0002-8903-4906)
- Scott David Solomon (ORCID: https://orcid.org/0000-0003-3698-9597)
- Muthiah Vaduganathan (ORCID: https://orcid.org/0000-0003-0885-1953)
- Jil Mamza (ORCID: https://orcid.org/0000-0001-7649-4332)
- Ross T. Campbell (ORCID: https://orcid.org/0000-0002-0050-2129)
- Benjamin R. Heywood
- Ruiqi Zhang (ORCID: https://orcid.org/0000-0003-3475-7557)
- Christopher Ll. Morgan
- Katherine Mullin
- Mark C Petrie
Institutions
- AstraZeneca (United Kingdom) (GB)
- University of Copenhagen (DK)
- Brigham and Women's Hospital (US)
- Copenhagen University Hospital (DK)
- Gentofte Hospital (DK)
- Rigshospitalet (DK)
- AstraZeneca (South Korea) (KR)
- AstraZeneca (France) (FR)
- AstraZeneca (Poland) (PL)
- Hospital Universitari Germans Trias i Pujol (ES)
- University of Glasgow (GB)
- Cardiff University (GB)
Publication Details
- Journal
- European Heart Journal
- Published
- 2025-08-18
- DOI
- https://doi.org/10.1093/eurheartj/ehaf675
- Citations
- 4
- Primary Topic
- Heart Failure Treatment and Management
- Type
- article
- Field-Weighted Citation Impact
- 5.55
Funders
- Amgen
- Eli Lilly and Company
- AstraZeneca
- Bayer
- Sanofi
- Alnylam Pharmaceuticals
- Boston Scientific Corporation
- Regeneron Pharmaceuticals
- Ionis Pharmaceuticals
- Cytokinetics
- Moderna
- Horizon Therapeutics
- Insmed
- British Heart Foundation
- University of Glasgow
- Novo Nordisk
- Intas Pharmaceuticals
- National Institutes of Health
- Relypsa
- National Heart, Lung, and Blood Institute